Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, Scatton B. Curet O, et al. Among authors: bergis o. J Affect Disord. 1998 Dec;51(3):287-303. doi: 10.1016/s0165-0327(98)00225-0. J Affect Disord. 1998. PMID: 10333983 Review.
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.
Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B. Biton B, et al. Among authors: bergis oe. Neuropsychopharmacology. 2007 Jan;32(1):1-16. doi: 10.1038/sj.npp.1301189. Epub 2006 Oct 4. Neuropsychopharmacology. 2007. PMID: 17019409
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.
Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B. Cohen C, et al. Among authors: bergis oe. J Pharmacol Exp Ther. 2003 Jul;306(1):407-20. doi: 10.1124/jpet.103.049262. Epub 2003 Apr 7. J Pharmacol Exp Ther. 2003. PMID: 12682217
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B. Pichat P, et al. Neuropsychopharmacology. 2007 Jan;32(1):17-34. doi: 10.1038/sj.npp.1301188. Epub 2006 Aug 23. Neuropsychopharmacology. 2007. PMID: 16936709
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stemmelin J, et al. Among authors: bergis o. Neuropsychopharmacology. 2008 Feb;33(3):574-87. doi: 10.1038/sj.npp.1301424. Epub 2007 Apr 25. Neuropsychopharmacology. 2008. PMID: 17460614
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B. Boulay D, et al. Among authors: bergis o. Pharmacol Biochem Behav. 2008 Nov;91(1):47-58. doi: 10.1016/j.pbb.2008.06.009. Epub 2008 Jun 24. Pharmacol Biochem Behav. 2008. PMID: 18621075
20 results